Company Profile
Lepu Biopharma Co., Ltd., a biopharmaceutical company focuses on the discovery, development, and commercialization of drug candidates in anti-tumor targeted therapy and oncology immunotherapy in China and globally. The company offers PUYOUHENG (Pucotenlimab Injection), a humanized IgG4 mAb against human PD-1 for the treatment of MSI-H/dMMR solid tumors solid tumors and melanoma.
It is also developing MRG003 that is in phase III clinical study for treating nasopharyngeal cancer, and head and neck squamous cell carcinoma. Its portfolio also includes CMG901 CLDN18.2-targeted ADC, which is in phase III trials for treating gastric and gastroesophageal junction carcinoma and solid tumors, and MRG004A TF-targeted ADC, which is in phase III clinical trial for treating pancreatic ductal adenocarcinoma.
Additionally, it is developing CG00705 Oncolytic virus for treating bacillus calmette-guerin unresponsive non-muscle invasive bladder cancer; and MRG002, which is in phase III trials to treat breast cancer
HER2-positive. It also is developing MRG001 CD20-targeted ADC for treating non-Hodgkin's lymphoma; MRG006A, MRG007, and CTM012 for the treatment of solid tumors. Incorporated in 2018, Lepu Biopharma is headquartered in Shanghai, China. Lepu Biopharma Co., Ltd. operates as a subsidiary of Ningbo Houde Yimin Information Technology Co., Ltd.